11.03.2015 • News

Wacker “Examines Options” for Siltronic

Wacker Chemie has confirmed market rumors that it may spin off or float its semiconductor subsidiary Siltronic. The Munich-based company said management has submitted to the supervisory board "appropriate plans" for a separation of the wholly owned business.

The most favoured strategic option under consideration appears to be an initial public offering, whereby Wacker did not reveal whether it planned to sell all of its shares.

"Reshaping Siltronic's ownership structure could be beneficial for both Wacker and Siltronic," said Wacker CEO Rudolf Staudigl. With the income from a flotation, he said, the former parent company could free up funds to invest in its chemical and polysilicon operations.

Such a move also could reduce the overall capital intensity, the CEO added, while noting that Siltronic "could harness additional growth opportunities by accessing the capital markets itself."

"A further option, Wacker said, is a sale to a strategic investor. "A detailed analysis of all the possible courses of action is necessary first to see how far these goals are achievable and which path would then be appropriate," Staudigl said.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read